Qlife Holding AB (publ) is pleased to announce that it publishes a second balance sheet for liquidation purposes showing that the Company's total equity exceeds the registered share capital
Qlife Holding AB (publ) (“Qlife” or the “Company”) has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act (“ABL”), prepared a second balance sheet for liquidation purposes, which has been reviewed by the Company's auditor. The balance sheet shows that the Company's total equity exceeds the registered share capital.
On 21 March 2024, the Company presented a balance sheet for liquidation purposes, showing that the equity was less than half of the registered share capital. On 28 March 2024, Qlife announced that the rights issue, approved by the extraordinary general meeting on 16 January 2024, had been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). The Company received gross proceeds amounting to approximately MSEK 30.10 from the rights issue, whereby the Company’s equity increased by the same amount. Additionally, the Company announced on 8 May 2024, that all outstanding convertible debentures were converted into shares, resulting in an equity increase of approximately MSEK 3.66 in the Company. At the extraordinary general meeting, the first meeting for liquidation purposes, held on 23 April 2024, it was decided that the Company's operations would continue. According to the Swedish Companies Act, the Company is required to hold a second meeting for liquidation purposes within eight months. On 29 August 2024, the Company published the unaudited Q2-report, showing that the Company’s equity exceeds the registered share capital. Therefore, the Company prepared a balance sheet for liquidation purposes which now has been reviewed by the Company's auditor. The balance sheet for liquidation purposes shows that the equity exceeds the registered share capital.
The board of directors will call for an extraordinary general meeting, the second meeting for liquidation purposes, where the question of whether the Company should continue its operations or go into liquidation will be reconsidered. Since the second balance sheet shows that the equity in relation to the registered share capital is fully restored, the Company's board of directors will propose continued operations, with liquidation as a secondary option.
“We are happy that the equity is restored and that we can concentrate on what is really important, to move towards commercialization of our product platform, and hence some shareholder value.” – Thomas Warthoe, CEO of Qlife Holding AB (publ)
The second balance sheet for liquidation purposes will be available on the Company's website www.qlifeholding.com. It is also attached to this press release in PDF format.
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (”Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.